In an alliance that illustrates the growing attractiveness of rising innovative R&D capabilities at selected Chinese pharma firms, the US oncology-focused company Incyte Corp. has acquired development and commercialization rights in most global markets to SHR-1210, a PD-1-targeting antibody developed by Jiangsu Hengrui Medicine Co. Ltd.
The deal is worth $25m up front and up to $770m in milestone fees, plus tiered royalties. Hengrui retains rights...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
